Commentary: New Complications Make Treatment of “Opioid” Overdose Challenging

Peppin, John F.; Pergolizzi, Joseph V.; Dahan, Albert; Raffa, Robert B.

doi:10.4236/pp.2020.1112029

Cited by 1 publication

(1 citation statement)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 To prevent or treat hypoxic events, agnostic respiratory stimulators may be utilized. 16 This study aimed to assess the effect of ENA-001 on propofol-induced depression of the HVR in human volunteers. The results of this study will provide valuable information on ENA-001’s ability to overcome depression of the HVR induced within brainstem respiratory networks.…”

Section: Editor’s Perspectivementioning

confidence: 99%

Reversal of Propofol-induced Depression of the Hypoxic Ventilatory Response by BK-channel Blocker ENA-001: A Randomized Controlled Trial

Jansen,

van Lemmen,

Olofsen

et al. 2024

Anesthesiology

Self Cite

View full text Add to dashboard Cite

Background The use of anesthetics may result in depression of the hypoxic ventilatory response. Since there are no receptor-specific antagonists for most anesthetics, there is the need for agnostic respiratory stimulants, that increase respiratory drive irrespective of its cause. We tested whether ENA-001, an agnostic respiratory stimulant that blocks carotid body BK-channels, could restore the hypoxic ventilatory response during propofol infusion. We hypothesize that ENA-001 is able to fully restore the hypoxic ventilatory response. Methods In this randomized double-blind cross-over trial, 14 male and female healthy volunteers were randomized to receive placebo, low and high dose ENA-001 on three separate occasions. On each occasion, isohypercapnic hypoxic ventilatory responses were measured during a fixed sequence of placebo, followed by low- and high-dose propofol infusion. We conducted a population pharmacokinetic/pharmacodynamic analysis that included oxygen and carbon dioxide kinetics. Results Twelve subjects completed the three sessions; no serious adverse events occurred. The propofol concentrations were 0.6 and 2.0 µg/mL at low- and high-dose, respectively. The ENA-001 concentrations were 0.6 and 1.0 µg/mL at low- and high-dose, respectively. The propofol concentration that reduced the hypoxic ventilatory response by 50% was 1.47±0.20 µg/mL. The steady-state ENA-001 concentration to increase the depressed ventilatory response by 50% was 0.51±0.04 µg/mL. A concentration of 1 µg/mL ENA-001 was required for full reversal of the propofol effect at its C50. Discussion In this pilot study, we demonstrated that ENA-001 restored the hypoxic ventilatory response impaired by propofol. This finding is not only of clinical importance, but also provides mechanistic insights into the peripheral stimulation of breathing with ENA-001 overcoming central depression by propofol.

show abstract

Section: Editor’s Perspectivementioning

confidence: 99%